Flexibility as Competitive Advantage
Mega-merged companies have to find twice as many drugs or drugs which are twice as valuable. But there are fewer such opportunities as managed care lifts higher innovation hurdles for manufacturers, particularly in developing the widely-used chroniccare medicines that form the basis of most drug companies' profit statements.
You may also be interested in...
TransEnterix hires Shameze Rampertab as its new CFO and said it expects “modest growth” in Q3 and Q4.
Keeping Track: Viltepso Earns Priority Review Voucher; Manufacturing Trips Fennec; Eagle Drops Ryanodex Exertional Heat Stroke Bid
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
CureVac raised hundreds of millions of dollars this year before its $213m initial public offering as its mRNA vaccine technology moved into the COVID-19 spotlight. Its stock price tripled on its debut.